title: Soluble complement receptor type 1 protects rats from lethal shock induced by anti-Crry antibody following lipopolysaccharide priming.
abstract: BACKGROUND
  In rats primed with a trace amount of lipopolysaccharide (LPS), acute lethal shock is induced following the injection of monoclonal antibody against a membrane inhibitor of complement (anti-Crry). Administration of cobra venom factor to exhaust complement before the LPS priming can prevent the lethal reaction. Therefore, we evaluated whether soluble complement receptor type 1 (sCR1), which inhibits complement reaction, can interfere with lethal shock when administered after LPS priming or even after anti-Crry injection.
  
  
  METHODS
  sCR1 was administered intravenously before or after the administration of anti-Crry, and the effects on blood pressure and acute lethality were determined.
  
  
  RESULTS
  Administration of sCR1 could rescue rats from lethal shock even when it was administered after anti-Crry injection, which immediately causes a blood pressure decrease leading to lethal shock.
  
  
  CONCLUSIONS
  sCR1 may be an effective treatment for acute shock involving complement activation.
authors.affiliation: Third Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Mizuno
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Noriko
authors.initials: N
authors.lastname: Okada
authors.forename: Seiichi
authors.initials: S
authors.lastname: Matsuo
authors.forename: Hidechika
authors.initials: H
authors.lastname: Okada
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D000954:Antigens, Surface; D003167:Complement Activation; D005455:Fluorescent Antibody Technique; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D011956:Receptors, Cell Surface; D011951:Receptors, Complement / Q000276:immunology* / Q000378:metabolism; D017463:Receptors, Complement 3b / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012772:Shock, Septic / Q000209:etiology / Q000517:prevention & control*; D012995:Solubility
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; C513105:Cr1l protein, rat; D008070:Lipopolysaccharides; D011956:Receptors, Cell Surface; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D011994:Recombinant Proteins